Login to Your Account



An Obesity/Diabetes Path with Heart

The Fat and the Furiex: Could FDA Wins Help Contrave Bid?

By Randy Osborne
Staff Writer

Tuesday, January 29, 2013
The FDA's marketing clearance of three alogliptin-containing drugs for Type II diabetes as adjuncts to diet and exercise sent Furiex Pharmaceuticals Inc. on a happy Wall Street ride, at the same time causing onlookers to speculate about what the approvals might mean for the obesity candidate Contrave, which – like alogliptin – is partnered with Takeda Pharmaceutical Co. Ltd.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription